IL6 and prostate carcinoma: In addition, in vitro studies have demonstrated that IL-6-dependent activation of the JAK/STAT3 pathway is accompanied by transition from hormone-sensitive to hormone-insensitive prostate cancer cell growth (Lee et al, 2003).